Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01297400 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
A Phase 2 study of Burns, sponsored by Skingenix.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 6
- Study locations
NCT01297400 is a Phase 2 study of Burns that is actively recruiting participants, run by Skingenix. The registered enrollment target is 60 participants, below the 82-participant average among 36 other Burns trials with a reported enrollment target (27% lower). The trial reports 6 study locations across 5 states.
The verdict
NCT01297400, a Phase 2 study of Burns, is actively recruiting participants, sponsored by Skingenix.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 6
- Study locations
Study Summary
To compare MW-III to Silvadene® Cream 1% (Silver Sulfadiazine) with respect to "time to healing" (≥95% re-epithelialization) of a partial thickness target thermal burn.
Conditions Studied
Interventions
- DRUG Investigational Drug, MW-III
- DRUG Silvadene® Cream 1% [Silver Sulfadiazine]
Study Locations (6)
Other
- Proactive CR Mexico SA de CV - Irapuato
- SMIQ S de R. L de CV - Querétaro City
Arizona
- Valleywise Health Medical Center - Phoenix
California
- University of CA Davis Medical Center - Sacramento
District of Columbia
- MedStar Washington Hospital Center - Washington D.C.
Iowa
- University of Iowa Health Care - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2022-03-11 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01297400
The ClinicalTrials.gov registry entry for NCT01297400 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 82-participant average among 36 other Burns trials with a reported enrollment target (27% lower). The listed sponsor is Skingenix, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Burns appearing as the primary indexed condition, and to 2 interventions - of which Investigational Drug, MW-III is the first listed.
NCT01297400 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Other, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT01297400 about?
NCT01297400 is a clinical study titled "Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns". To compare MW-III to Silvadene® Cream 1% (Silver Sulfadiazine) with respect to "time to healing" (≥95% re-epithelialization) of a partial thickness target thermal burn.
What is the current status of trial NCT01297400?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2022-03-11. Estimated completion is 2026-12-31.
What conditions does trial NCT01297400 study?
This clinical trial studies the following conditions: Burns.
What interventions are being tested in trial NCT01297400?
The interventions under investigation include: Investigational Drug, MW-III (DRUG), Silvadene® Cream 1% [Silver Sulfadiazine] (DRUG).
Who is sponsoring clinical trial NCT01297400?
This trial is sponsored by Skingenix, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01297400 being conducted?
This trial has 6 study locations across Arizona, California, District of Columbia, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Burns
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
4-Aminopyridine to Treat Skin Burns
RECRUITING · Phase 2
-
Cranial Electrotherapy Stimulation in Burned Patients
COMPLETED · Phase 2
-
VR for Burn Dressing Changes at Home
COMPLETED · Phase 2
-
Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)
COMPLETED · Phase 2
-
Suprathel® Use During Prolonged Field Care to Promote Healing and Reduce the Need for Grafting of Burn Wounds
RECRUITING · NA
-
Liposomal Bupivacaine Versus Lidocaine for Skin Graft Donor Site Pain
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.